Angiotensin receptor blocker neprilysin inhibitors

doi:10.4330/wjc.v13.i8.325

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6506)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

603

WORD

196

HTML

4001

Figures (1-3)

394

Tables (1-1)

252

Sum=5446

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

388

Download

672

Sum=1060

Aug 26, 2021 (publication date) through Dec 3, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Cardiol. Aug 26, 2021; 13(8): 325-339
Published online Aug 26, 2021. doi: 10.4330/wjc.v13.i8.325

Open in New Tab Full Size Figure Download Figure

Figure 1 Three neurohumoral factors related to the pathology of chronic heart failure, and the targets of conventional remedies. ACEI: Angiotensin-converting enzyme inhibitors; ARB: Angiotensin receptor blockers; BB: β-blocker; BP: Blood pressure; HF: Heart failure; HR: Heart rate; MRA: Mineralocorticoid receptor antagonist; RAAS: Renin-angiotensin-aldosterone-system.

Open in New Tab Full Size Figure Download Figure

Figure 2 Mechanism of sacubitril/valsartan on heart failure progression. AT1: Angiotensin II type 1; HF: Heart failure; NP: Natriuretic peptide; RAAS: Renin-angiotensin-aldosterone-system; SAC/VAL: Sacubitril/valsartan.

Open in New Tab Full Size Figure Download Figure

Figure 3 The therapeutic options and treatment lines of patients with symptoms of heart failure with reduced ejection fraction. ACEI: Angiotensin-converting enzyme inhibitor; AF: Atrial fibrillation; ARB: Angiotensin receptor blocker; ARNI: Angiotensin receptor neprilysin inhibitor; BB: β-blocker; bpm: Beats per minute; CRT: Cardiac resynchronization therapy; HR: Heart rate; ICD: Implantable cardioverter defibrillator; LVEF: Left ventricular ejection fraction; MRA: Mineralocorticoid receptor antagonist; NYHA: New York Heart Association; SR: Sinus rhythm.

Citation: Usuda D, Higashikawa T, Hotchi Y, Usami K, Shimozawa S, Tokunaga S, Osugi I, Katou R, Ito S, Yoshizawa T, Asako S, Mishima K, Kondo A, Mizuno K, Takami H, Komatsu T, Oba J, Nomura T, Sugita M. Angiotensin receptor blocker neprilysin inhibitors. World J Cardiol 2021; 13(8): 325-339
URL: https://www.wjgnet.com/1949-8462/full/v13/i8/325.htm
DOI: https://dx.doi.org/10.4330/wjc.v13.i8.325